AZD8186 + Docetaxel for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug (AZD8186) combined with chemotherapy (docetaxel) in patients with advanced solid tumors with specific genetic mutations. The new drug aims to block enzymes needed for cancer growth, while the chemotherapy helps kill or stop the spread of cancer cells. AZD8186 has shown enhanced efficacy when combined with other treatments.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot take medications that strongly affect CYP3A4 enzymes. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What safety information is available for the combination of AZD8186 and Docetaxel in treating advanced cancer?
Docetaxel, also known as Taxotere, has been associated with side effects like neutropenia (low white blood cell count), alopecia (hair loss), skin reactions, and fluid retention. In some cases, it has also been linked to a scleroderma-like illness (a condition causing hardening and tightening of the skin).12345
What makes the drug AZD8186 + Docetaxel unique for advanced cancer treatment?
What data supports the effectiveness of the drug AZD8186 + Docetaxel for advanced cancer?
Research shows that combining docetaxel with PI3K inhibitors, like GDC-0941 and PX-866, enhances the effectiveness of docetaxel in treating cancers such as breast cancer and non-small cell lung cancer by increasing cancer cell death. This suggests that AZD8186, a similar PI3K inhibitor, might also improve the effectiveness of docetaxel in advanced cancer.15789
Who Is on the Research Team?
Alison M Schram
Principal Investigator
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have specific mutations (PTEN or PIK3CB) and can't be removed by surgery or have spread. Participants must be able to take oral meds, have no major gastrointestinal issues affecting drug absorption, and agree to use contraception. Prior treatments are allowed; however, prior treatment with PI3K/AKT inhibitors or certain other conditions may disqualify a person.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 orally twice daily for 5 days each week. Cycles repeat every 21 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Docetaxel
- PI3Kbeta Inhibitor AZD8186
Docetaxel is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor